Literature DB >> 33486694

Bosentan-induced immune hemolytic anemia in 17 years old man. A case report.

Fatemeh Afra1, Marjan Mehri2, Soha Namazi3,4.   

Abstract

Hemolytic anemia is a very important immune-mediated reaction, which its late diagnosis can be fatal. Medications along with other causes can induce hemolytic anemia. Drug induced immune hemolytic anemia (DIIHA) is caused by the development of autoantibodies. Accordingly, DIIHA is rare and there is not enough data for its prevalence. Number of drugs that can cause DIIHA have increased in recent decades. A 17-year-old man who had congenital single ventricle heart (CHB) and pulmonary artery hypertension (PAH) was admitted at Imam Khomeini hospital complex affiliated to Tehran University of Medical Sciences, with chief complaint of jaundice and icter. Bosentan and Tadalafil were in the list of the drugs used by this patient. Although both drugs were recommended to be discontinued in the patient, in the course of hospitalization, the patient accidentally continued to take his Tadalafil. However, the patient's recovery continued. Given that the patient's Coombs test was positive, his hemolytic anemia mechanism was drug-induced immune-mediated hemolytic anemia. As a result, according to Naranjo score = 6, Bosentan was considered as the main possible culprit to induce DIIHA in this patient. Following the discontinuation of Bosentan and receiving Prednisolone, the patient's clinical symptoms and laboratory parameters resolved and the patient was then discharged.

Entities:  

Keywords:  Bosentan; Congenital heart block (CHB); Drug-induced immune hemolytic anemia (DIIHA); Hemolytic anemia; Pulmonary artery hypertension (PAH)

Mesh:

Substances:

Year:  2021        PMID: 33486694      PMCID: PMC8149573          DOI: 10.1007/s40199-020-00386-1

Source DB:  PubMed          Journal:  Daru        ISSN: 1560-8115            Impact factor:   3.117


  17 in total

1.  Hemolytic anemia secondary to mesantoin.

Authors:  I SNAPPER; D MARKS; L SCHWARTZ; L HOLLANDER
Journal:  Ann Intern Med       Date:  1953-09       Impact factor: 25.391

2.  Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.

Authors:  Robyn J Barst; Kamal K Mubarak; Roberto F Machado; Kenneth I Ataga; Raymond L Benza; Oswaldo Castro; Robert Naeije; Namita Sood; Paul S Swerdlow; Mariana Hildesheim; Mark T Gladwin
Journal:  Br J Haematol       Date:  2010-02-17       Impact factor: 6.998

Review 3.  Warm Autoimmune Hemolytic Anemia.

Authors:  Robert A Brodsky
Journal:  N Engl J Med       Date:  2019-08-15       Impact factor: 91.245

4.  Intentional rechallenge and the clinical management of drug-related problems.

Authors:  Ronald Meyboom
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

5.  Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study.

Authors:  Edeltraut Garbe; Frank Andersohn; Elisabeth Bronder; Andreas Klimpel; Michael Thomae; Hubert Schrezenmeier; Martin Hildebrandt; Ernst Späth-Schwalbe; Andreas Grüneisen; Beate Mayer; Abdulgabar Salama; Hanife Kurtal
Journal:  Br J Haematol       Date:  2011-07-12       Impact factor: 6.998

6.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Ceftriaxone-Induced Hemolytic Anemia: A Rare Case Report.

Authors:  Sandeep Kumar; Rohit Bansal; Priya Bansal; Rajinder Kumar Dhamija; Dnb Neurology
Journal:  Perm J       Date:  2019-12-18

8.  Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

Authors:  M Humbert; E S Segal; D G Kiely; J Carlsen; B Schwierin; M M Hoeper
Journal:  Eur Respir J       Date:  2007-05-15       Impact factor: 16.671

Review 9.  Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.

Authors:  Christopher J Valerio; John G Coghlan
Journal:  Vasc Health Risk Manag       Date:  2009-08-06

Review 10.  Review of bosentan in the management of pulmonary arterial hypertension.

Authors:  Eli Gabbay; John Fraser; Keith McNeil
Journal:  Vasc Health Risk Manag       Date:  2007
View more
  2 in total

1.  Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption.

Authors:  Yuanjun Wu; Yong Wu; Yong Yang; Baochan Chen; Jianqun Li; Ganping Guo; Fu Xiong
Journal:  Front Immunol       Date:  2021-12-22       Impact factor: 7.561

2.  Association between NAD+ levels and anaemia among women in community-based study.

Authors:  Fan Yang; Xuguang Zhang; Feifei Hu; Ye Yu; Lei Luo; Xuan Deng; Yuzheng Zhao; Bo Pan; Jinping Zheng; Yugang Qiu; Jun Guo; Feng Xiao; Xiaomei Xie; Zhenyu Ju; Yong Zhou
Journal:  J Cell Mol Med       Date:  2022-04-06       Impact factor: 5.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.